Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02437487 · ClinicalTrials.gov registry record · Phase 2
SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)
A Phase 2 study of Clostridium Difficile, sponsored by Seres Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 89
- Enrollment target
- 20
- Study locations
NCT02437487 is a Phase 2 study of Clostridium Difficile that has completed, run by Seres Therapeutics. The registered enrollment target is 89 participants, below the 447-participant average among 6 other Clostridium Difficile trials with a reported enrollment target (80% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT02437487, a Phase 2 study of Clostridium Difficile, has completed, sponsored by Seres Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 89 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study will involve administering the study drug as a single dose of study drug or placebo. This study is designed to demonstrate the superiority of the experimental drug versus placebo in adult patients with recurrent CDI.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG SER-109
Study Locations (20)
Florida
- ZASA Clinical Research - Atlantis
- Omega Research Consultants LLC - DeBary
- Borland-Groover Clinic - Jacksonville
- Gastroenterology Group of Naples - Naples
- Advanced Medical Research Center - Port Orange
California
- North County Gastroenterology - Oceanside
- University Of California Davis - Sacramento
- Ventura Clinical Trials - Ventura
Maryland
- Anne Arundel Health System Research Institute - Annapolis
- Johns Hopkins Bayview Medical - Baltimore
- Metropolitan Gastroenterolgy Group Pc - Chevy Chase
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Med Cntr - Boston
Georgia
- Emory University - Atlanta
Idaho
- Idaho Falls Infection Diseases - Idaho Falls
Louisiana
- Ochsner Clinic Foundation - New Orleans
Michigan
- William Beaumont Hospital - Royal Oak
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 89 participants |
| Start Date | 2015-05 |
| Est. Completion | 2016-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02437487
The ClinicalTrials.gov registry entry for NCT02437487 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 89 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 447-participant average among 6 other Clostridium Difficile trials with a reported enrollment target (80% lower). The listed sponsor is Seres Therapeutics, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Clostridium Difficile appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02437487 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Florida, California, Maryland.
Frequently Asked Questions
What is clinical trial NCT02437487 about?
NCT02437487 is a clinical study titled "SER-109 Versus Placebo to Prevent Recurrent Clostridium Difficile Infection (RCDI)". The study will involve administering the study drug as a single dose of study drug or placebo. This study is designed to demonstrate the superiority of the experimental drug versus placebo in adult patients with recurrent CDI.
What is the current status of trial NCT02437487?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 89 participants. The study started on 2015-05. Estimated completion is 2016-10.
What conditions does trial NCT02437487 study?
This clinical trial studies the following conditions: Clostridium Difficile.
What interventions are being tested in trial NCT02437487?
The interventions under investigation include: Placebo (DRUG), SER-109 (DRUG).
Who is sponsoring clinical trial NCT02437487?
This trial is sponsored by Seres Therapeutics, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02437487 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Idaho, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clostridium Difficile
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study
COMPLETED · Phase 2
-
Study of Nitazoxanide in the Treatment of Clostridium Difficile Colitis
COMPLETED · Phase 2
-
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
RECRUITING · Phase 3
-
Dynamics of Colonization and Infection by Multidrug-Resistant Pathogens in Immunocompromised and Critically Ill Patients
RECRUITING
-
REMBRANDT: REcovery of the MicroBiome fRom Antibiotics for Dental implanTs
ACTIVE NOT RECRUITING
-
Early FMT for C.Difficile
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.